Literature DB >> 29576463

Risk factors for appendiceal and colorectal peritoneal metastases.

Malin Enblad1, Wilhelm Graf2, Helgi Birgisson2.   

Abstract

BACKGROUND: Early diagnosis to target minimal volume disease has received increased attention in the management of appendiceal and colorectal peritoneal metastases (PM). This study aimed to identify risk factors for appendiceal, colon and rectal PM.
METHODS: Data were retrieved from the Swedish Colorectal Cancer Registry for all patients undergoing bowel resection of appendiceal and colorectal tumours, in Sweden, 2007-2015. Risk factors for synchronous and metachronous PM were analysed with multivariate logistic and Cox proportional hazard regression models.
RESULTS: Synchronous PM was most common in appendiceal cancer (23.5%), followed by colon (3.1%) and rectal (0.6%) cancer. The 5-year cumulative incidence was 9.0% for appendiceal, 2.5% for right colon, 1.8% for left colon and 1.2% for rectal cancer. In appendiceal cancer (n = 327), T4, N2, mucinous tumour, and non-radical surgery were associated with PM. In colon cancer (n = 24,399), synchronous PM were primarily associated with T4 (OR 18.37, 95% CI 8.12-41.53), T3 and N2 but also with N1, right-sided tumour, mucinous tumour, vascular and perineural invasion, female gender, age <60 and emergency surgery. These factors were also associated with metachronous PM. In rectal cancer (n = 10,394), T4 (OR 19.12, 95% CI 5.52-66.24), proximal tumour and mucinous tumour were associated with synchronous PM and T4 and mucinous tumour with metachronous PM.
CONCLUSIONS: This study shows that appendiceal cancer, right-sided colon cancer, advanced tumour and node stages and mucinous histopathology are the main high-risk features for PM and should increase the awareness of current or future PM.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Appendiceal cancer; Colorectal cancer; Peritoneal metastases; Risk factors

Mesh:

Year:  2018        PMID: 29576463     DOI: 10.1016/j.ejso.2018.02.245

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

Review 1.  Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review.

Authors:  Phillip J Hsu; Khushboo Singh; Ankit Dhiman; Hunter D D Witmer; Chuan He; Oliver S Eng; Daniel V T Catenacci; Mitchell C Posner; Kiran K Turaga
Journal:  JCO Precis Oncol       Date:  2022-02

2.  Application of Imaging Indicators Based on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Colorectal Peritoneal Carcinomatosis.

Authors:  Chun-Feng Sun; Ding Zhang; Yan Gao; Xiao-Ying Mao; Zhong-Hua Tan; Shan-Lei Bao; Chen Shen
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Diagnostic impact of ascites cytology in 941 patients: malignancy rates and time of detection in ovarian cancer relative to other tumor types.

Authors:  Jens Krugmann; Corinna Lang Schwarz; Balint Melcher; William Sterlacci; Michael Vieth; Sophia Rösch; Johannes Lermann
Journal:  Arch Gynecol Obstet       Date:  2020-04-28       Impact factor: 2.344

4.  MicroRNA-937 is overexpressed and predicts poor prognosis in patients with colon cancer.

Authors:  Huiya Liu; Lin Ma; Ling Wang; Yizuo Yang
Journal:  Diagn Pathol       Date:  2019-12-19       Impact factor: 2.644

5.  Locally advanced perforated appendiceal cancer: Case report and review.

Authors:  Samik H Patel; Sharon Bihlmeyer; John C Eggenberger; Beth-Ann Shanker; Robert K Cleary
Journal:  Clin Case Rep       Date:  2022-02-11

6.  Metastatic Mucinous Adenocarcinoma of Gastrointestinal Origin: A Rare Presentation of Peritoneal Carcinomatosis in a Woman.

Authors:  Krista M Wong; Mohammad Haidous; Zain AlShanableh; Poornanand Palaparty; Keyvan Ravakhah
Journal:  Cureus       Date:  2022-02-23

7.  Molecular characterization of colorectal cancer related peritoneal metastatic disease.

Authors:  Jurriaan B Tuynman; Louis Vermeulen; Kristiaan J Lenos; Sander Bach; Leandro Ferreira Moreno; Sanne Ten Hoorn; Nina R Sluiter; Sanne Bootsma; Felipe A Vieira Braga; Lisanne E Nijman; Tom van den Bosch; Daniel M Miedema; Erik van Dijk; Bauke Ylstra; Ruth Kulicke; Fred P Davis; Nicolas Stransky; Gromoslaw A Smolen; Robert R J Coebergh van den Braak; Jan N M IJzermans; John W M Martens; Sally Hallam; Andrew D Beggs; Geert J P L Kops; Nico Lansu; Vivian P Bastiaenen; Charlotte E L Klaver; Maria C Lecca; Khalid El Makrini; Clara C Elbers; Mark P G Dings; Carel J M van Noesel; Onno Kranenburg; Jan Paul Medema; Jan Koster; Lianne Koens; Cornelis J A Punt; Pieter J Tanis; Ignace H de Hingh; Maarten F Bijlsma
Journal:  Nat Commun       Date:  2022-08-04       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.